Original-Research: Hoenle AG (von NuWays AG): BUY

Classification of NuWays AG to Hoenle AG

Company Name: Hoenle AG

ISIN: DE0005157101

Reason for the research: Update

Recommendation: BUY

Target price: EUR 15

Target price on sight of: 12 months

Last rating change:

Analyst: Sarah Hellemann

Q1 25/26: Ahead where it matters, waiting on market momentum

Yesterday, Hoenle released its Q1 (Oct - Dec) figures for FY 25/26 with a

stronger than expected bottom-line. In detail:

Revenue came in flat-ish yoy at EUR 21.5m, slightly below expectations (eNuW:

EUR 22.2m). A weakness in Curing stemming from a sustained customer reluctance

to invest was largely compensated by strong growth in Disinfection.

Adhesives developed in line with expectations.

EBITDA remained ahead of expectations (eNuW: EUR -0.1m) and came in at EUR 0.5m

(-49% yoy). Stronger than anticipated developments in Disinfection and a

positive contribution from Adhesives partially mitigated slower demand in

Curing, exchange rate differences, material cost inflation. Higher marketing

expenses are expected to result in higher sales in following quarters.

Disinfection beat estimates with 18% yoy sales growth to EUR 6.7m (eNuW: EUR

5.7m) and a 91% yoy jump in EBITDA contribution, which stood at EUR 1.0m

(eNuW: EUR 0.7m). Key driver was a strong end-market demand, especially for

water disinfection systems.

Adhesives performed flat-ish, despite a negative effect from exchange rate

differences with a revenue contribution of EUR 8.1m, slightly ahead of

expectations (eNuW: EUR 8.0m). Higher medical demand offset weaker

Curing-related adhesive demand. Adhesives delivered a positive EBITDA

contribution of EUR 0.8m slightly ahead of expectations (eNuW: EUR 0.7m), but at

-33% yoy.

Curing showed a particularly weak performance with revenue falling by 13% to

EUR 6.6m (eNuW: EUR 8.5m), due to low investment activity of customers.

Reflecting this circumstance and despite restructuring efforts taken in

2025, EBITDA came in at EUR -1.2m (eNuW: EUR 0m).

Currently at an inflection point, Hoenle showed further improvements.

Decreasing trade receivables resulted in a positive operating cash flow of EUR

0.2m, ahead of EUR -0.6m in the previous year. Slight deleveraging raised the

equity ratio from 52.9% to 53.3%. Hoenle showed improved confidence for H2

2026 on account of market expansion plans through partnerships in North

America and India as well as efforts to boost after-sales activities.

Further cost-cutting measures should additionally support the bottom line.

Looking to FY 25/26, we expect growth across segments to support a 4.8% yoy

rise in revenue to EUR 98.2m (eNuW). Disinfection is supported by strong

tailwinds and an increasing interest in their water purification solutions.

While customer investments have been low for some time, there are growth

opportunities in stronger after-sales activities (i. e. changing to LED

ahead of regular replacement cycles) and in assisting in extending equipment

lifecycles. Key catalyst remains a recovery of CAPEX-investments among

customers, with improvements indicated by VDMA (+1% yoy growth for 2026).

Adhesives should profit from stronger Curing sales and end market demand, i.

e. in medical.

With top-line growth ahead, right-sizing efforts from 2025 starting to show

and further cost control expected, EBITDA should rise by 22% yoy to EUR 7.1m.

The confirmed guidance of EUR 95-105m (eNuW: EUR 98m) in revenue and EUR 6-9m in

EBITDA appears achievable. Maintaining BUY with a PT of EUR 15.

You can download the research here:

https://eqs-cockpit.com/c/fncls.ssp?u=597619704470d4106f85bf277b92efe0

For additional information visit our website:

https://www.nuways-ag.com/research-feed

Contact for questions:

NuWays AG - Equity Research

Web: www.nuways-ag.com

Email: research@nuways-ag.com

LinkedIn: https://www.linkedin.com/company/nuwaysag

Adresse: Mittelweg 16-17, 20148 Hamburg, Germany

Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss

bestimmter Börsengeschäfte.

Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben

analysierten Unternehmen befindet sich in der vollständigen Analyse.

The EQS Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

View original content:

https://eqs-news.com/?origin_id=7e0a053e-121b-11f1-8534-027f3c38b923&lang=en

2281120 25.02.2026 CET/CEST

°